The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.
List view / Grid view
Filter the results
The US FDA has awarded pemigatinib Priority Review, after the drug met its primary and secondary endpoints in a Phase II trial.
Learn how Adaptimmune, a leader in developing T cell cancer therapies, implemented Lonza’s MODA™ Solution to manage information in QC micro lab more efficiently.
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
A new drug delivery system disguises chemo-therapeutics as fat in order to destroy tumours.
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
The National Institute for Health and Care Excellence is recommending MSD’s Prevymis (letermovir) within the NHS.
The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer.
The retail prices of some anti-cancer drugs have been cut by 87 percent by the drug price control authority in India.
Merck wins award for first-of-its-kind, single-use tangential flow filtration capsule used in ADC and monoclonal antibody bioprocessing...
This article covers the analytical criteria that apply to Bacterial Endotoxin Testing (BET) using Limulus Amebocyte Lysate (LAL) or recombinant Horseshoe crab Factor C (rFC) for the bioactivity determination of endotoxin in aqueous solutions, such as pharmaceuticals and medical device extracts. It explains the importance of these criteria for accurate…
The FDA has approved the first ever non-chemotherapy combination treatment using ibrutinib and obinutuzumab for the most common form of adult leukaemia...
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
Erleada (apalutamide) has been approved for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
The Almac Group, a CDMO serving the pharmaceutical and biotech sectors globally, is expanding its Edinburgh Technopole facility to allow scale-up of its personalised cancer vaccine activities...